TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31977921
Drug: Infrared sauna
Normalized name: Sana leaf
DrugBank: Senna leaf (DB15889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrared sauna treatment
Study: 27067394
Drug: Sonidegib 200
Normalized name: sonidegib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonidegib 200 mg
Study: 27262419
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg IV‐TXA before skin incision (group A)
Study: 27262419
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg IV‐TXA 3 hours later (group B)
Study: 27262419
Drug: Two boluses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two boluses of 10 mg/kg IV‐TXA at 3 and 6 hours later (group C)
Study: 25722196
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg q24h for 9 months)
Study: 25722196
Drug: Isoniazid (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid (300 mg q24h for 9 months)
Study: 23052809
Drug: Intravenous cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cefazolin 1 g
Study: 20642418
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 3-monthly spirometry with regular medical review
Study: 18821166
Drug: Activating both
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activating both the solutions and blocking words for a particular fragment at study
Study: 12061361
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of indomethacin (n = 14)
Study: 12061361
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of indomethacin (n = 18)
Study: 2110199
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg per injection of IFN, subcutaneous injections three times weekly
Study: 2110199
Drug: 0.02 mg
Normalized name: escin 0.02 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg of IFN, subcutaneous injections three times weekly
Study: 2110199
Drug: Placebo, subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, subcutaneous injections three times weekly
Study: 6110582
Drug: Standard-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose oral contraceptives (50 microgram of estrogen)
Study: 6110582
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptives (30 microgram of estrogen)
Study: 6110582
Drug: Both standard-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both standard-dose and low-dose oral contraceptives
Study: 2678880
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptives
Study: 31904309
Drug: 250 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL distilled water with 10-minute rest in a supine position
Study: 31904309
Drug: 250 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL distilled water with 30-minute rest in a supine position
Study: 25733482
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplement (LNS) fortified with multiple micronutrients (MMNs)
Study: 25733482
Drug: MMN supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMN supplement
Study: 24657484
Drug: TG4040 followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TG4040 followed by PEG‐IFNα/RBV for 48 weeks with 6 injections of TG4040 (group C)
Study: 24657484
Drug: PEG‐IFNα/RBV for
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFNα/RBV for 4 weeks followed by PEG‐IFNα/RBV for 44 weeks with 6 injections of TG4040 (group B)
Study: 8959472
Drug: Lesopitron 20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesopitron 20, 25, 30, 40, 45, 50, and 60 mg two times a day
Study: 8959472
Drug: Lesopitron 60
Normalized name: Lesopitron
DrugBank: Lesopitron (DB04970)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesopitron 60 mg two times a day
Study: 8959472
Drug: Lesopitron (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesopitron (various doses)
Study: 1304766
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IGIV) 500 mg/kg
Study: 12357165
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine infusion
Study: 18848786
Drug: Estramustine (E)
DrugBank: Estramustine phosphate (DB14674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estramustine (E) 840 mg/day divided into three daily administrations on days 1-5 plus DOC 70 mg/m² on day 2
Study: 15800138
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no anti-Alzheimer drugs)
Study: 27537360
Drug: Blue LED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue LED light treatment (emission maximum: 453 nm), 3 times per week for 4 weeks
Study: 25047311
Drug: 1% feracrylum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% feracrylum citrate solution
Study: 17942609
Drug: Peptide-DC vaccine
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide-DC vaccine (3 million versus 10 million) administered intravenously or subcutaneously
Study: 17942609
Drug: Peptide-DC vaccine
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide-DC vaccine
Study: 15696987
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% clindamycin solution
Study: 8913976
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of PGE2 gel
Study: 8913976
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg of PGE2 gel
Study: 1859518
Drug: CM 40907
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM 40907 (1200 mg)
Study: 1859518
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA, 1000 mg)
Study: 1859518
Drug: CM 40907
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM 40907 (600 mg and 900 mg)
Study: 6355052
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir treatment (200 mg, 5 times daily) for first episode HSV
Study: 6355052
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir treatment for recurrent HSV
Study: 24332218
Drug: BI 671800
Normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 671800 (200 mg twice daily)
Study: 24332218
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate nasal spray (200 μg once daily)
Study: 24332218
Drug: BI 671800
Normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 671800 (all doses)
Study: 15711245
Drug: Chronic urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic urinary retention with large residual urine volumes (greater than 300 ml)
Study: 12193309
Drug: Single enema
Normalized name: docusate
DrugBank: Docusate (DB11089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single enema (400 mg of PTU in 90 mL of sterile water)
Study: 12193309
Drug: Two suppositories
Normalized name: potassium bitartrate / sodium bicarbonate Rectal Suppository [Ceo-Two]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two suppositories of polyethylene glycol base (200 mg of PTU in each)
Study: 12193309
Drug: Both forms
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both forms of PTU (enema and suppository)
Study: 16879331
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser preparation
Study: 16942429
Drug: Conventional mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional mechanical preparation
Study: 27431570
Drug: Kang'ai Xiaoshui
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kang'ai Xiaoshui ointment
Study: 23870239
Drug: Lidocaine pump
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine pump spray
Study: 18666504
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L-Pop
Study: 19132414
Drug: Two experimental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two experimental formulations
Study: 11255136
Drug: Potassium phosphate
Normalized name: Potassium phosphate
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium phosphate supplementation (4,000 mg x day(-1) for 2 days)
Study: 9875688
Drug: Grape procyanidin
Normalized name: procyanidin A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape procyanidin extracts (Leucoselect-phytosome) 300 mg, taken as two capsules daily for 5 days.
Study: 9875688
Drug: Placebo, taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken as two capsules daily for 5 days.
Study: 2603606
Drug: Other forms
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other forms of treatment (Group B)
Study: 31128926
Drug: Enhanced upper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced upper limb therapy (EULT)
Study: 18162423
Drug: Glutamate or
Normalized name: glutamate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamate or Capsaicin injection
Study: 10555884
Drug: Alendronate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (40 mg oral AL/day)
Study: 1974748
Drug: Beta‐adrenoceptor blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta‐adrenoceptor blocking agents (treated group, n = 39)
Study: 1974748
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 22, no preoperative beta-blocker therapy)
Study: 15998890
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg every other day)
Study: 11860644
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray administration
Study: 11860644
Drug: Nasal drop
Normalized name: Nasal Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal drop administration
Study: 10442381
Drug: UFT (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (150 mg/m2/day) plus oral calcium folinate (90 mg/day) plus radiotherapy (45 Gy total)
Study: 7844596
Drug: Chemotherapy (CHEMO)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CHEMO)
Study: 2895592
Drug: Midazolam 15
Normalized name: midazolam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 15 mg and Temazepam 20 mg
Study: 23886213
Drug: GEMOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEMOX regimen (gemcitabine at 1000 mg/m² by fixed-dose rate infusion at 10 mg/m²/min on days 1 and 8, and oxaliplatin at 100 mg/m² on day 1, repeated every 3 weeks)
Study: 23886213
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (gemcitabine at 1000 mg/m² by intravenous infusion within 30 min on days 1 and oxaliplatin at 100 mg/m² on day 1, repeated every 3 weeks)
Study: 20541220
Drug: Olanzapine augmentation
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine augmentation (olanzapine + divalproex)
Study: 3394908
Drug: Diazepam in
Normalized name: diazePAM Intensol
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam in lipid formulation
Study: 30740748
Drug: Gabapentin (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (maximum daily dose of 900 mg)
Study: 30740748
Drug: Baclofen (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (maximum daily dose of 60 mg)
Study: 29964036
Drug: Genotypic resistance-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotypic resistance-guided therapy for 14 days (n=21 in trial 1, n=205 in trial 2)
Study: 29964036
Drug: Empirical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical therapy for 14 days (n=20 in trial 1, n=205 in trial 2)
Study: 29964036
Drug: Doxycycline sequential
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline sequential therapy (part of trial 1)
Study: 22915637
Drug: DAS 100
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAS 100 mg/day
Study: 22915637
Drug: IM 400
Normalized name: Bactrim 400mg-80mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM 400 mg/day
Study: 11581440
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate (IR MPH) 3 times a day (tid)
Study: 2646838
Drug: Premedication with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedication with 10 mg isosorbide dinitrate sublingually
Study: 28281196
Drug: Inhalation via
Normalized name: propyliodone 60 % INHALATION VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation via I‐neb®
Study: 28281196
Drug: Inhalation via
Normalized name: propyliodone 60 % INHALATION VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation via Turbuhaler®
Study: 28281196
Drug: Inhalation via
Normalized name: propyliodone 60 % INHALATION VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation via new dry powder inhaler (new DPI)
Study: 28281196
Drug: Inhalation via
Normalized name: propyliodone 60 % INHALATION VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation via Spira®
Study: 28281196
Drug: Predicted lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predicted lung deposited dose
Study: 18444532
Drug: Oral captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral captopril (25 mg)
Study: 18444532
Drug: Oral nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nicardipine (20 mg)
Study: 14979419
Drug: Controllable perfusion-related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controllable perfusion-related variables during CPB (e.g., hematocrit, mean arterial pressure, thermic perfusion, blood lactate, colloid osmotic pressure, pulsatile perfusion, acid base homeostasis, oxygenation, coated circuitry)
Study: 10548210
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with a bolus of 1.5 mg piritramide and a 10-min lockout interval
Study: 10548210
Drug: PCA combined
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA combined with nonsteroidal anti-inflammatory drugs prescribed three times per day
Study: 1899325
Drug: Theophylline (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (250 mg three or four times a day)
Study: 22149452
Drug: Potassium supplementation
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium supplementation (100 mmol daily)
Study: 18635722
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR 75-225 mg/day
Study: 8915561
Drug: Fluoxetine 20-60
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20-60 mg/day
Study: 7673949
Drug: Chlorambucil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil (0.1 mg/kg/day orally for 12 months)
Study: 2169778
Drug: Granisetron (40-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (40-200 micrograms/kg, 30 min infusion)
Study: 2169778
Drug: Granisetron (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (160 micrograms/kg, 3 min infusion)
Study: 28197938
Drug: Taohong Siwu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taohong Siwu Decoction (TSD) plus oral prednisone
Study: 28197938
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus oral prednisone
Study: 29231407
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (methotrexate)
Study: 22459966
Drug: Eritoran 4
Normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eritoran 4 mg
Study: 17242095
Drug: Eritoran 12
Normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eritoran 12 mg
Study: 17242095
Drug: Eritoran 28
Normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eritoran 28 mg
Study: 22459966
Drug: Eritoran (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eritoran (all doses)
Study: 20855800
Drug: Palifermin (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palifermin (180 µg per kg of body weight) administered intravenously as a single dose 3 days before each chemotherapy cycle (maximum, 6 cycles)
Study: 18249119
Drug: Chemotherapy (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (various agents and schedules)
Study: 18249119
Drug: Chemotherapy clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy clinical trial
Study: 18249119
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in patients over 60 years
Study: 12915290
Drug: Olanzapine 5-15
Normalized name: olanzapine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5-15 mg daily
Study: 16918641
Drug: Topical vitamin
Normalized name: vitamin A Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vitamin E
Study: 6374682
Drug: miconazole/hydrocortisone preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: miconazole/hydrocortisone preparation
Study: 6374682
Drug: nystatin/benzalkonium chloride/dimethicone/hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: nystatin/benzalkonium chloride/dimethicone/hydrocortisone preparation
Study: 2876035
Drug: Latamoxef 6g
Normalized name: latamoxef
DrugBank: Latamoxef (DB04570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Latamoxef 6g daily for 7 days
Study: 2876035
Drug: Latamoxef 3g
Normalized name: latamoxef
DrugBank: Latamoxef (DB04570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Latamoxef 3g daily for 7 days
Study: 26538525
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide group (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg)
Study: 20420113
Drug: Ginger (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (1 gram of dried powder suspended in 100 ml water)
Study: 15659136
Drug: Steroid avoidance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid avoidance (SA) with basiliximab, cyclosporine (CsA), and mycophenolate mofetil (MMF)
Study: 30265586
Drug: Steroid avoidance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid avoidance (SA)
Study: 15659136
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with steroids tapered to 5 mg prednisone/d by day 30
Study: 2997387
Drug: Intranasal high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal high-dose interferon
Study: 2997387
Drug: Intranasal low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal low-dose interferon
Study: 25236994
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (sunitinib)
Study: 22358993
Drug: TACE with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE with multiple anticancer drugs (epirubicin, cisplatin, mitomycin C, 5-fluorouracil)
Study: 20163368
Drug: Ranibizumab 0.3
Normalized name: RANIBIZUMAB 0.3MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.3 mg (Group B)
Study: 20163368
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg (Group B)
Study: 17403436
Drug: Single-agent and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent and combined treatments
Study: 17403436
Drug: Metformin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (n = 6)
Study: 16234141
Drug: Intravaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal misoprostol (50 mug every 6 h for a maximum of two doses)
Study: 16234141
Drug: Intracervical Foley
Normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical Foley balloon catheter (for 12 h followed by intravenous oxytocin infusion)
Study: 12163990
Drug: Selective lymph
Normalized name: Bos taurus lymph preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective lymph node dissection after hyperfractionated accelerated radio-(chemo-)therapy
Study: 12163990
Drug: Hyperfractionated accelerated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfractionated accelerated radio-(chemo-)therapy
Study: 10793877
Drug: Disodium pamidronate
Normalized name: Disodium pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium pamidronate 300 mg/day for 4 weeks every 16 weeks (group A)
Study: 10793877
Drug: Disodium pamidronate
Normalized name: Disodium pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium pamidronate 150 mg/day for 4 weeks every 8 weeks (group B)
Study: 8992677
Drug: Observation period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation period of 22 months with cladribine treatment